Thermo Fisher Scientific Inc. (NYSE: TMO) reported its financial results for the third quarter ended September 26, 2026, in a filing dated October 21, 2026. The company announced that revenue for the quarter grew 9% to $12.14 billion, compared to $11.12 billion in the same period of the prior year. Organic revenue growth for the quarter was reported at 6%.
On an earnings basis, GAAP diluted earnings per share (EPS) increased 9% to $4.64, while adjusted EPS grew 15% to $6.68. GAAP operating income for the quarter was $2.26 billion, representing an 17% increase compared to the prior year, resulting in a GAAP operating margin of 18.6% versus 17.4% in the third quarter of 2025. Adjusted operating income was $2.97 billion, with an adjusted operating margin of 24.5%.
The company highlighted product launches during the quarter, including the Thermo Scientific Orbitrap Isora mass spectrometer, the EMPAD G2 electron detector, the FDA-cleared EliA CTD 13 Screen, and the Ion 560 Chip. Additionally, Thermo Fisher completed the divestiture of its microbiology business during the quarter.
Thermo Fisher also noted the opening of an AI-Automation Innovation Center in South Korea and a highly automated distribution center in Kentucky. The company stated that it will provide updated 2026 financial guidance during its earnings conference call scheduled for October 21, 2026, at 7:00 a.m. Eastern Time.
